Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-808-3 | CAS number: 110-85-0
Acute Toxicity: other routes
Administrative data
- Endpoint:
- acute toxicity: other routes
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Basic data given
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 964
- Report date:
- 1964
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- other: BASF-test following internal SOP
- GLP compliance:
- no
- Remarks:
- pre-GLP
- Limit test:
- no
Test material
- Reference substance name:
- Piperazine
- EC Number:
- 203-808-3
- EC Name:
- Piperazine
- Cas Number:
- 110-85-0
- Molecular formula:
- C4H10N2
- IUPAC Name:
- piperazine
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Piperazine, technical grade
- no further data
Test animals
- Species:
- mouse
- Strain:
- not specified
- Sex:
- male/female
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- water
- Doses:
- 25, 50, 100, 125, 160, 200, 1600 mg/kg bw
- No. of animals per sex per dose:
- 25, 50, 100, 1600 mg/kg bw: 5 animals
125, 160, 200 mg/kg bw: 10 animals - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations: several times on the day of application, at least once per day thereafter
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 125 mg/kg bw
- Mortality:
- 1600 mg/kg dosing group: 5/5
200 mg/kg dosing group: 10/10
160 mg/kg dosing group: 9/10
late deaths reported
125 mg/kg dosing group: 6/10
100 mg/kg dosing group: 0/5
50 mg/kg dosing group: 0/5
25 mg/kg dosing group: 0/5 - Clinical signs:
- following substance administration: slightly unsteady gait, intermitted respiration, shrunken flanks
following days: apathy, scrubby coat, crusted eyes, survivors recovered till day 12, the animals of the lower dosing group (25-100 mg/kg) appeared normal on day 1 after application. - Body weight:
- no data
- Gross pathology:
- deceased animals: strong gastrointestinal irritation, pale livers, hyperaemia in the accessory sex glands
Applicant's summary and conclusion
- Conclusions:
- LD50 for intraperitoneal route is 125 mg/kg bw.
- Executive summary:
Rats were dosed with piperazine by intraperitoneal injection at 7 doselevels. The LD50 was 125 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
